U-41792

U-41792 is a small molecule developed by the Upjohn Company as a hypobetalipoproteinemic agent, meaning it lowers levels of beta-lipoproteins, including low-density lipoprotein such as apolipoprotein B, in the blood. Elevated LDL levels can lead to early-onset atherosclerosis and increase the risk of heart problems.
U-41792 demonstrated its ability to reduce lipid levels in hyperlipemic rats.

Synthesis

In order to synthesize U-41792, the alcohol of adamantane called 1-adamantanol is reacted with sodium to generate its corresponding alkoxide. This alkoxide then undergoes a nucleophilic aromatic substitution on p-fluoronitrobenzene to form the corresponding ether. This nitro group is then reduced and alkylated to give U-41792.
N.B. 4-Fluoronitrobenzene has dual use in the synthesis of B777-81 & WAY-213,613 also.